Connection

Co-Authors

This is a "connection" page, showing publications co-authored by NAOTO T UENO and WILLIAM F SYMMANS.
Connection Strength

1.498
  1. Phase 2 study of neoadjuvant enzalutamide and paclitaxel for luminal androgen receptor-enriched TNBC: Trial results and insights into "ARness". Cell Rep Med. 2024 Jun 18; 5(6):101595.
    View in: PubMed
    Score: 0.243
  2. Bone metastasis-related signaling pathways in breast cancers stratified by estrogen receptor status. J Cancer. 2017; 8(6):1045-1052.
    View in: PubMed
    Score: 0.148
  3. Gene signature-guided dasatinib therapy in metastatic breast cancer. Clin Cancer Res. 2014 Oct 15; 20(20):5265-71.
    View in: PubMed
    Score: 0.123
  4. Novel functional assay for spindle-assembly checkpoint by cyclin-dependent kinase activity to predict taxane chemosensitivity in breast tumor patient. J Cancer. 2013; 4(9):697-702.
    View in: PubMed
    Score: 0.117
  5. Latest biopsy approach for suspected metastases in patients with breast cancer. Nat Rev Clin Oncol. 2013 Dec; 10(12):711-9.
    View in: PubMed
    Score: 0.116
  6. Differential response to neoadjuvant chemotherapy among 7 triple-negative breast cancer molecular subtypes. Clin Cancer Res. 2013 Oct 01; 19(19):5533-40.
    View in: PubMed
    Score: 0.115
  7. Different gene expressions are associated with the different molecular subtypes of inflammatory breast cancer. Breast Cancer Res Treat. 2011 Feb; 125(3):785-95.
    View in: PubMed
    Score: 0.095
  8. PTEN in triple-negative breast carcinoma: protein expression and genomic alteration in pretreatment and posttreatment specimens. Ther Adv Med Oncol. 2023; 15:17588359231189422.
    View in: PubMed
    Score: 0.057
  9. Predictive Roles of Baseline Stromal Tumor-Infiltrating Lymphocytes and Ki-67 in Pathologic Complete Response in an Early-Stage Triple-Negative Breast Cancer Prospective Trial. Cancers (Basel). 2023 Jun 21; 15(13).
    View in: PubMed
    Score: 0.057
  10. Targeting chemotherapy resistance in mesenchymal triple-negative breast cancer: a phase II trial of neoadjuvant angiogenic and mTOR inhibition with chemotherapy. Invest New Drugs. 2023 Jun; 41(3):391-401.
    View in: PubMed
    Score: 0.056
  11. Prognostic Impact of High Baseline Stromal Tumor-Infiltrating Lymphocytes in the Absence of Pathologic Complete Response in Early-Stage Triple-Negative Breast Cancer. Cancers (Basel). 2022 Mar 04; 14(5).
    View in: PubMed
    Score: 0.052
  12. Immune Phenotype and Response to Neoadjuvant Therapy in Triple-Negative Breast Cancer. Clin Cancer Res. 2021 10 01; 27(19):5365-5375.
    View in: PubMed
    Score: 0.050
  13. Imaging features of triple-negative breast cancers according to androgen receptor status. Eur J Radiol. 2019 May; 114:167-174.
    View in: PubMed
    Score: 0.042
  14. Decreased expression of microRNA-26b in locally advanced and inflammatory breast cancer. Hum Pathol. 2018 07; 77:121-129.
    View in: PubMed
    Score: 0.040
  15. MicroRNA expression profiling identifies decreased expression of miR-205 in inflammatory breast cancer. Mod Pathol. 2016 Apr; 29(4):330-46.
    View in: PubMed
    Score: 0.034
  16. Gene expression profiles of inflammatory breast cancer: correlation with response to neoadjuvant chemotherapy and metastasis-free survival. Ann Oncol. 2014 Feb; 25(2):358-65.
    View in: PubMed
    Score: 0.029
  17. Comparison of molecular subtype distribution in triple-negative inflammatory and non-inflammatory breast cancers. Breast Cancer Res. 2013 Nov 25; 15(6):R112.
    View in: PubMed
    Score: 0.029
  18. A network-based, integrative study to identify core biological pathways that drive breast cancer clinical subtypes. Br J Cancer. 2012 Mar 13; 106(6):1107-16.
    View in: PubMed
    Score: 0.026
  19. Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol. 2012 Mar 01; 30(7):729-34.
    View in: PubMed
    Score: 0.026
  20. A genomic predictor of response and survival following taxane-anthracycline chemotherapy for invasive breast cancer. JAMA. 2011 May 11; 305(18):1873-81.
    View in: PubMed
    Score: 0.025
  21. B cell translocation gene 1 contributes to antisense Bcl-2-mediated apoptosis in breast cancer cells. Mol Cancer Ther. 2006 Jun; 5(6):1593-601.
    View in: PubMed
    Score: 0.017
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.